Where we began
It all started as a curious dorm room inquiry at Brown University in 2013. After learning that neurodegenerative disease is the result of neuronal death, Amylyx co-founder Josh Cohen couldn't help but ask himself one simple question: "Why do neurons die?" It seemed like such an obvious starting point yet the solution was nowhere to be found.
After poring over an extensive supply of research, Josh and a classmate, co-founder Justin Klee, posed that question — and started the journey of uncovering the answers. Overcoming obstacle after obstacle, contracting with lab after lab, and formulating test after test, they eventually accumulated sufficient data to pursue the next steps.
In the years since, their partnership has transformed into Amylyx, a rapidly growing pharmaceutical company with the same curiosity and resilience as the day our company began. That simple question considered back in 2013 has led to a clinical reality — a new investigational product, AMX0035, currently in clinical development for the treatment of both amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.